99459-52-6

Usage

Uses

Used in Pharmaceutical Industry:
(2-Methoxy-5-nitrophenyl)acetonitrile is used as an intermediate in the synthesis of various pharmaceutical compounds for its unique structure and properties.
Used in Agrochemical Industry:
(2-Methoxy-5-nitrophenyl)acetonitrile is used as a building block in the development of agrochemicals, contributing to the creation of effective products for agricultural applications.
Used in Organic Chemistry Research:
(2-Methoxy-5-nitrophenyl)acetonitrile is used as a valuable compound in organic chemistry research for its potential in various chemical reactions and its unique structure.
Used in Medicinal Chemistry and Drug Discovery:
(2-Methoxy-5-nitrophenyl)acetonitrile is used as a target for research in medicinal chemistry and drug discovery due to its potential biological activity and its role as an important intermediate in the synthesis of various compounds.

InChI:InChI=1S/C9H8N2O3/c1-14-9-3-2-8(11(12)13)6-7(9)4-5-10/h2-3,6H,4H2,1H3

Upstream product

• 151-50-8 potassium cyanide 
• 93-06-1 2-chloromethyl-4-nitroanisole 
• 3913-23-3 2-methoxy-5-nitrobenzyl bromide 
• 100-17-4 para-methoxynitrobenzene 
• 143-33-9 sodium cyanide 

Downstream Products

• 109069-72-9 (2-methoxy-5-nitro-phenyl)-acetyl chloride 
• 90557-39-4 2-(5-amino-2-methoxyphenyl)acetonitrile 
• 51073-04-2 (2-methoxy-5-nitro-phenyl)-acetic acid 
• 102309-06-8 (2-methoxy-5-nitro-phenyl)-acetic acid amide 

Relevant academic research and scientific papers

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS

The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.

N-phenyl-N-acetamidoglycinamides, their preparation and medicaments containing them

Compounds of formula: STR1 in which R1 represents a hydrogen atom or an alkyl, alkoxycarbonyl or an unsubstituted or substituted phenyl radical, R2 represents a hydrogen atom or an unsubstituted or substituted alkyl radical, R3 represents an alkyl, phenylalkyl, indanyl, cycloalkylalkyl or an unsubstituted or substituted phenyl radical, or R2 and R3 form a heterocycle together with the nitrogen atom to which they are attached, and R4 represents an unsubstituted or substituted phenyl radical, a naphthyl, indolyl or quinolyl radical or a phenylamino radical in which the phenyl ring is unsubstituted or substituted, their preparation and medicaments containing them.